Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data. (2021)
Attributed to:
Oesophago-gastric adenocarcinoma: understanding disease pathogenesis and applications to earlier diagnosis
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.eclinm.2021.100969
PubMed Identifier: 34195582
Publication URI: http://europepmc.org/abstract/MED/34195582
Type: Journal Article/Review
Volume: 37
Parent Publication: EClinicalMedicine
ISSN: 2589-5370